(RTTNews) - Shares of 4D Molecular Therapeutics (FDMT) are up over 26% to $5.69 in premarket trading Friday, following positive 60-week data from its Phase II SPECTRA trial.

D Molecular Therapeutics advances 4D-150 for wet AMD and DME, revealing promising trial results and regulatory progress for ...

Leerink lowered the firm’s price target on 4D Molecular (FDMT) to $16 from $17 and keeps an Outperform rating on the shares after the company annou ...